Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.53% | 3.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.19% | -9.60% | |||
| Operating Income | 20.19% | 9.60% | |||
| Income Before Tax | 19.36% | 10.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.41% | 10.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.41% | 10.08% | |||
| EBIT | 20.19% | 9.60% | |||
| EBITDA | 20.19% | 9.60% | |||
| EPS Basic | 21.70% | 15.76% | |||
| Normalized Basic EPS | 21.66% | 15.83% | |||
| EPS Diluted | 21.70% | 15.76% | |||
| Normalized Diluted EPS | 21.66% | 15.83% | |||
| Average Basic Shares Outstanding | 2.94% | 6.74% | |||
| Average Diluted Shares Outstanding | 2.94% | 6.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||